Peer-influenced content. Sources you trust. No registration required. This is HCN.

The New England Journal of MedicineGlofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

The researchers enrolled DLBCL patients with relapsed or refractory disease who had already received at least two lines of treatment in the phase 2 portion of a phase 1-2 investigation. They concluded that treatment with glofitamab was successful for DLBCL, with more than half of the patients experiencing a grade 3 or 4 adverse event.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form